11 results
2021 ACR/VF Guidelines for Management of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

#Granulomatosis #Polyangiitis #GPA
2021 ACR/VF Guidelines ... for Management ... #ACR2021 #Management ... #rheumatology # ... algorithm #vasculitis
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
for Treatment & ... Polyangiitis (MPA ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Polyangiitis (MPA ... Algorithm - ACR ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
2021 ACR/VF Guidelines for Management of Polyarteritis Nodosa (PAN)

#PAN #Polyarteritis #Nodosa #ACR2021 #Management #rheumatology #algorithm #vasculitis
2021 ACR/VF Guidelines ... for Management ... #Nodosa #ACR2021 ... #Management #rheumatology ... #algorithm #vasculitis
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
Algorithm - ACR ... /VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Algorithm - ACR ... of Preference (Can ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
Algorithm - ACR ... /VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Takayasu's Arteritis (TAK) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active TAK not on
Algorithm - ACR ... /VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
pathway likely an ... • Avoid ARB/ACE-I ... /ARNI/MRA • Avoid ... e.g., <50%), ESC guidelines ... #cardiology #treatment
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
CALR-calreticulin gene, or MPL-thrombopoietin ... • Treatment algorithms ... Thrombocythemia #ET #hematology ... #diagnosis #management ... #hematology